Cancer Research Cancer Epigenetics Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tu, Y.
Right arrow Articles by Lichtenstein, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tu, Y.
Right arrow Articles by Lichtenstein, A.
[Cancer Research 60, 6763-6770, December 1, 2000]
© 2000 American Association for Cancer Research

Tumor Biology

The Phosphatidylinositol 3-Kinase/AKT Kinase Pathway in Multiple Myeloma Plasma Cells: Roles in Cytokine-dependent Survival and Proliferative Responses1

Yiping Tu, Agnes Gardner and Alan Lichtenstein2

Department of Medicine, West LA VA Medical Center, and Jonsson Comprehensive Cancer Center, Los Angeles, California, 90073

Interleukin 6 (IL-6) and insulin-like growth factor I (IGF-I) induce proliferative and antiapoptotic responses in multiple myeloma (MM) plasma cells. Because these cytokines may activate the phosphatidylinositol 3-kinase (PI 3-K)/AKT kinase pathway in other cell types, we investigated the role of PI 3-K/AKT in MM cell responses. IGF-I effectively activated PI 3-K in 8226 and OCI-My5 MM cells, but IL-6 was ineffective. However, IL-6 successfully activated PI 3-K in AF-10 MM cells and IL-6-dependent MH.60 plasmacytoma/hybridoma cells. IGF-I also successfully activated PI 3-K in four of four MM patient specimens, and IL-6 activated PI 3-K in three of four specimens. Inhibition of PI 3-K activity with wortmannin or Ly294002 blocked the antiapoptotic effect of IGF-I and the proliferative effect of IL-6 in the myeloma cell lines. Furthermore, a dominant negative PI 3-K construct, expressed in AF-10 cells by adenoviral infection, also significantly inhibited the IL-6 proliferative response in MM cells. In correlation with activation of PI 3-K, IGF-I also effectively activated the AKT kinase in 8226 and OCI-My5 cells, and IL-6 activated AKT in AF-10 and MH.60 cells. However, although incapable of activating PI 3-K in 8226 and OCI-My5 cells, IL-6 successfully activated AKT in these MM lines, suggesting PI 3-K-independent mechanisms of AKT activation. The prevention of a myeloma cell proliferative response resulting from inhibition of PI 3-K activity was not associated with an inhibition of IL-6-dependent extracellular signal-regulated kinase (ERK) activation. These results support a role for the PI 3-K/AKT pathway in cytokine-dependent responses in myeloma cells, which is independent of any activation of the ERK pathway.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. S. Turner, L. P. Kane, and P. A. Morel
Dominant Role of Antigen Dose in CD4+Foxp3+ Regulatory T Cell Induction and Expansion
J. Immunol., October 15, 2009; 183(8): 4895 - 4903.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Burger, S. Le Gouill, Y.-T. Tai, R. Shringarpure, P. Tassone, P. Neri, K. Podar, L. Catley, T. Hideshima, D. Chauhan, et al.
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
Mol. Cancer Ther., January 1, 2009; 8(1): 26 - 35.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Zollinger, T. Stuhmer, M. Chatterjee, S. Gattenlohner, E. Haralambieva, H.-K. Muller-Hermelink, M. Andrulis, A. Greiner, C. Wesemeier, J. C. Rath, et al.
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma
Blood, October 15, 2008; 112(8): 3403 - 3411.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. David, R. Sinha, J. Chen, S.-Y. Sun, J. L. Kaufman, and S. Lonial
Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors
Clin. Cancer Res., August 15, 2008; 14(16): 5090 - 5098.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Leleu, J. Eeckhoute, X. Jia, A. M. Roccaro, A.-S. Moreau, M. Farag, A. Sacco, H. T. Ngo, J. Runnels, M. R. Melhem, et al.
Targeting NF-{kappa}B in Waldenstrom macroglobulinemia
Blood, May 15, 2008; 111(10): 5068 - 5077.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Huston, X. Leleu, X. Jia, A.-S. Moreau, H. T. Ngo, J. Runnels, J. Anderson, Y. Alsayed, A. Roccaro, S. Vallet, et al.
Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment
Clin. Cancer Res., February 1, 2008; 14(3): 865 - 874.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
A. K. Pathak, M. Bhutani, A. S. Nair, K. S. Ahn, A. Chakraborty, H. Kadara, S. Guha, G. Sethi, and B. B. Aggarwal
Ursolic Acid Inhibits STAT3 Activation Pathway Leading to Suppression of Proliferation and Chemosensitization of Human Multiple Myeloma Cells
Mol. Cancer Res., September 1, 2007; 5(9): 943 - 955.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Kiziltepe, T. Hideshima, K. Ishitsuka, E. M. Ocio, N. Raje, L. Catley, C.-Q. Li, L. J. Trudel, H. Yasui, S. Vallet, et al.
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells
Blood, July 15, 2007; 110(2): 709 - 718.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. Liang, Y. Pan, D. Zhang, C. Guo, Y. Shi, J. Wang, Y. Chen, X. Wang, J. Liu, X. Guo, et al.
Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS
FASEB J, July 1, 2007; 21(9): 2247 - 2256.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. J. Bahlis, A. M. King, D. Kolonias, L. M. Carlson, H. Y. Liu, M. A. Hussein, H. R. Terebelo, G. E. Byrne Jr, B. L. Levine, L. H. Boise, et al.
CD28-mediated regulation of multiple myeloma cell proliferation and survival
Blood, June 1, 2007; 109(11): 5002 - 5010.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Chatterjee, S. Jain, T. Stuhmer, M. Andrulis, U. Ungethum, R.-J. Kuban, H. Lorentz, K. Bommert, M. Topp, D. Kramer, et al.
STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90{alpha} and {beta} in multiple myeloma cells, which critically contribute to tumor-cell survival
Blood, January 15, 2007; 109(2): 720 - 728.
[Abstract] [Full Text] [PDF]

Home page
 ASH-SAPHome page
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Hideshima, P. Neri, P. Tassone, H. Yasui, K. Ishitsuka, N. Raje, D. Chauhan, K. Podar, C. Mitsiades, L. Dang, et al.
MLN120B, a Novel I{kappa}B Kinase {beta} Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo.
Clin. Cancer Res., October 1, 2006; 12(19): 5887 - 5894.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Descamps, S. Wuilleme-Toumi, V. Trichet, C. Venot, L. Debussche, T. Hercend, M. Collette, N. Robillard, R. Bataille, and M. Amiot
CD45neg but Not CD45pos Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642
J. Immunol., September 15, 2006; 177(6): 4218 - 4223.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Li, S. Cortez, T. Nakamachi, V. Batuman, and A. Arimura
Pituitary Adenylate Cyclase-Activating Polypeptide Is a Potent Inhibitor of the Growth of Light Chain-Secreting Human Multiple Myeloma Cells.
Cancer Res., September 1, 2006; 66(17): 8796 - 8803.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al.
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Blood, May 15, 2006; 107(10): 4053 - 4062.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Menu, H. Jernberg-Wiklund, T. Stromberg, H. De Raeve, L. Girnita, O. Larsson, M. Axelson, K. Asosingh, K. Nilsson, B. Van Camp, et al.
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
Blood, January 15, 2006; 107(2): 655 - 660.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Stromberg, S. Ekman, L. Girnita, L. Y. Dimberg, O. Larsson, M. Axelson, J. Lennartsson, U. Hellman, K. Carlson, A. Osterborg, et al.
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells
Blood, January 15, 2006; 107(2): 669 - 678.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Wang, J. Hayashi, and G. Serrero
PC Cell-Derived Growth Factor Confers Resistance to Dexamethasone and Promotes Tumorigenesis in Human Multiple Myeloma
Clin. Cancer Res., January 1, 2006; 12(1): 49 - 56.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Shi, H. Yan, P. Frost, J. Gera, and A. Lichtenstein
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade
Mol. Cancer Ther., October 1, 2005; 4(10): 1533 - 1540.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Buzzeo, S. Enkemann, R. Nimmanapalli, M. Alsina, M. G. Lichtenheld, W. S. Dalton, and D. M. Beaupre
Characterization of a R115777-Resistant Human Multiple Myeloma Cell Line with Cross-Resistance to PS-341
Clin. Cancer Res., August 15, 2005; 11(16): 6057 - 6064.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Hamasaki, T. Hideshima, P. Tassone, P. Neri, K. Ishitsuka, H. Yasui, N. Shiraishi, N. Raje, S. Kumar, D. H. Picker, et al.
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo
Blood, June 1, 2005; 105(11): 4470 - 4476.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Gauduchon, F. Gouilleux, S. Maillard, V. Marsaud, J.-M. Renoir, and B. Sola
4-Hydroxytamoxifen Inhibits Proliferation of Multiple Myeloma Cells In vitro through Down-Regulation of c-Myc, Up-Regulation of p27Kip1, and Modulation of Bcl-2 Family Members
Clin. Cancer Res., March 15, 2005; 11(6): 2345 - 2354.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. W.C.J. van de Donk, H. M. Lokhorst, E. H.J. Nijhuis, M. M.J. Kamphuis, and A. C. Bloem
Geranylgeranylated Proteins are Involved in the Regulation of Myeloma Cell Growth
Clin. Cancer Res., January 15, 2005; 11(2): 429 - 439.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Frost, F. Moatamed, B. Hoang, Y. Shi, J. Gera, H. Yan, P. Frost, J. Gibbons, and A. Lichtenstein
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
Blood, December 15, 2004; 104(13): 4181 - 4187.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood, August 1, 2004; 104(3): 607 - 618.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Brocke-Heidrich, A. K. Kretzschmar, G. Pfeifer, C. Henze, D. Loffler, D. Koczan, H.-J. Thiesen, R. Burger, M. Gramatzki, and F. Horn
Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation
Blood, January 1, 2004; 103(1): 242 - 251.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-W. Qiang, L. Yao, G. Tosato, and S. Rudikoff
Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells
Blood, January 1, 2004; 103(1): 301 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Hideshima, D. Chauhan, T. Hayashi, K. Podar, M. Akiyama, C. Mitsiades, N. MItsiades, B. Gong, L. Bonham, P. de Vries, et al.
Antitumor Activity of Lysophosphatidic Acid Acyltransferase-{beta} Inhibitors, a Novel Class of Agents, in Multiple Myeloma
Cancer Res., December 1, 2003; 63(23): 8428 - 8436.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. Duplomb, B. Chaigne-Delalande, P. Vusio, S. Raher, Y. Jacques, A. Godard, and F. Blanchard
Soluble Mannose 6-Phosphate/Insulin-Like Growth Factor II (IGF-II) Receptor Inhibits Interleukin-6-Type Cytokine-Dependent Proliferation by Neutralization of IGF-II
Endocrinology, December 1, 2003; 144(12): 5381 - 5389.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-T. Tai, K. Podar, L. Catley, Y.-H. Tseng, M. Akiyama, R. Shringarpure, R. Burger, T. Hideshima, D. Chauhan, N. Mitsiades, et al.
Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of {beta}1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling
Cancer Res., September 15, 2003; 63(18): 5850 - 5858.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. C. Platanias
Map kinase signaling pathways and hematologic malignancies
Blood, June 15, 2003; 101(12): 4667 - 4679.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Shi, J. Gera, J.-h. Hsu, B. Van Ness, and A. Lichtenstein
Cytoreductive Effects of Farnesyl Transferase Inhibitors on Multiple Myeloma Tumor Cells
Mol. Cancer Ther., June 1, 2003; 2(6): 563 - 572.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Lentzsch, M. Gries, M. Janz, R. Bargou, B. Dorken, and M. Y. Mapara
Macrophage inflammatory protein 1-alpha (MIP-1alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells
Blood, May 1, 2003; 101(9): 3568 - 3573.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Hu, Y. Shi, J.-h. Hsu, J. Gera, B. Van Ness, and A. Lichtenstein
Downstream effectors of oncogenic ras in multiple myeloma cells
Blood, April 15, 2003; 101(8): 3126 - 3135.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-T. Tai, K. Podar, N. Mitsiades, B. Lin, C. Mitsiades, D. Gupta, M. Akiyama, L. Catley, T. Hideshima, N. C. Munshi, et al.
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling
Blood, April 1, 2003; 101(7): 2762 - 2769.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Podar, Y.-T. Tai, C. E. Cole, T. Hideshima, M. Sattler, A. Hamblin, N. Mitsiades, R. L. Schlossman, F. E. Davies, G. J. Morgan, et al.
Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells
J. Biol. Chem., February 14, 2003; 278(8): 5794 - 5801.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Kortylewski, F. Feld, K.-D. Kruger, G. Bahrenberg, R. A. Roth, H.-G. Joost, P. C. Heinrich, I. Behrmann, and A. Barthel
Akt Modulates STAT3-mediated Gene Expression through a FKHR (FOXO1a)-dependent Mechanism
J. Biol. Chem., February 7, 2003; 278(7): 5242 - 5249.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Ringshausen, F. Schneller, C. Bogner, S. Hipp, J. Duyster, C. Peschel, and T. Decker
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta
Blood, November 15, 2002; 100(10): 3741 - 3748.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Chatterjee, D. Honemann, S. Lentzsch, K. Bommert, C. Sers, P. Herrmann, S. Mathas, B. Dorken, and R. C. Bargou
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway
Blood, October 16, 2002; 100(9): 3311 - 3318.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Shi, J. Gera, L. Hu, J.-h. Hsu, R. Bookstein, W. Li, and A. Lichtenstein
Enhanced Sensitivity of Multiple Myeloma Cells Containing PTEN Mutations to CCI-779
Cancer Res., September 1, 2002; 62(17): 5027 - 5034.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Hayashi, T. Hideshima, M. Akiyama, P. Richardson, R. L. Schlossman, D. Chauhan, N. C. Munshi, S. Waxman, and K. C. Anderson
Arsenic Trioxide Inhibits Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment
Mol. Cancer Ther., August 1, 2002; 1(10): 851 - 860.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Akiyama, T. Hideshima, T. Hayashi, Y.-T. Tai, C. S. Mitsiades, N. Mitsiades, D. Chauhan, P. Richardson, N. C. Munshi, and K. C. Anderson
Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line
Cancer Res., July 1, 2002; 62(13): 3876 - 3882.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-W. Qiang, E. Kopantzev, and S. Rudikoff
Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk
Blood, May 13, 2002; 99(11): 4138 - 4146.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Shi, J.-h. Hsu, L. Hu, J. Gera, and A. Lichtenstein
Signal Pathways Involved in Activation of p70S6K and Phosphorylation of 4E-BP1 following Exposure of Multiple Myeloma Tumor Cells to Interleukin-6
J. Biol. Chem., May 3, 2002; 277(18): 15712 - 15720.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Alkan and K. F. Izban
Immunohistochemical localization of phosphorylated AKT in multiple myeloma
Blood, March 15, 2002; 99(6): 2278 - 2279.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright
Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma
Hematology, January 1, 2002; 2002(1): 241 - 262.
[Abstract] [Full Text]

Home page
 BloodHome page
J.-h. Hsu, Y. Shi, S. Krajewski, S. Renner, M. Fisher, J. C. Reed, T. F. Franke, and A. Lichtenstein
The AKT kinase is activated in multiple myeloma tumor cells
Blood, November 1, 2001; 98(9): 2853 - 2855.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.